摘要
目的比较顺铂与卡铂联合紫杉醇同步化疗在宫颈癌患者中的价值。方法前瞻性收集我院2011年1月至2013年1月收治的宫颈癌患者86例,随机分为研究组和对照组,每组43例,研究组采用卡铂联合紫杉醇同步化疗,对照组采用顺铂联合紫杉醇同步化疗。主要观察指标为3年生存率、复发率、无进展生存期、实体瘤疗效评价等级、健康相关的生存质量(SF-36)和相关并发症。结果两组患者3年生存率、无进展生存期、术后1年实体瘤疗效评价等级和有效率比较差异均无统计学意义(P>0.05)。研究组患者复发率低于对照组(32.56%vs.55.81%,P=0.030);术后1年健康相关的生存质量(SF-36)高于对照组(77.30±6.72 vs.73.42±6.15,P=0.006)。两组患者化疗期间相关并发症发生率比较差异无统计学意义(P>0.05)。结论卡铂联合紫杉醇同步化疗有助于降低宫颈癌患者术后复发率,改善患者生存质量。
Objective To compare the efficacy of cisplatin and carboplatin in combination with paclitaxel chemotherapy for patients with cervical cancer.Methods Totally 86 patients with cervical cancer treated in our hospital from January 2011 to January 2013 were enrolled in the prospective study;they were randomly assigned into study group or control group,with 43 cases in each group.Study group was treated with carboplatin combined with paclitaxel chemotherapy,and control group was treated with cisplatin combined with paclitaxel chemotherapy.The primary outcomes included 3-year survival rate,recurrence rate,progression free survival,rate of solid tumor efficacy,health-related quality of life（SF-36） and related complications.Results There was no significant difference between the two groups in 3-year survival rate,progression free survival,1-year rating of solid tumor efficacy and effective rate（P〈0.05）.The recurrence rate in study group was lower than that of control group（32.56% vs.55.81%,P = 0.030）,while the SF-36 score in study group was higher（77.30 ± 6.72 vs.73.42 ± 6.15,P = 0.006）.There was no significant difference in rates of chemotherapy-related complications between the two groups（P〉0.05）.Conclusion Carboplatin combined with paclitaxel chemotherapy helps reduce the postoperative recurrence rate and improve the quality of life in patients with cervical cancer.
出处
《实用药物与临床》
CAS
2017年第8期887-890,共4页
Practical Pharmacy and Clinical Remedies
关键词
宫颈癌
顺铂
卡铂
紫杉醇
Cervical cancer
Cisplatin
Carboplatin
Paclitaxel
